WASHINGTON, D.C. — Moderna's prototype combination influenza and Covid vaccine outperformed currently authorized standalone shots for those viruses in a clinical trial, the US biotech firm said Monday.Other companies including Pfizer and Novavax are also working toward combination vaccines to fight respiratory illnesses, but Moderna is the first to report data from an advanced stage clinical rival, giving it a leg up on its rivals.
'Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses,' said CEO Stephane Bancel.Stephane Bancel, CEO of Moderna, speaks during the Semafor 2024 World Economy Summit in Washington, DC in Washington, DC, on April 18, 2024.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: gmanews - 🏆 11. / 68 Read more »